On the other hand, KRASG12V mutation could induce PD-L1 expression and promote immune escape via transforming growth factor-β/EMT signaling pathway in KRAS-mutant NSCLC [70,71], indicating the failure of PD-L1 targeting therapy using Pembrolizumab. This evidence concerns the gene KRAS and non-small cell lung carcinoma.